Hosted on MSN
Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer: Phase III trial
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback